Maplirpacept

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Maplirpacept
DrugBank Accession Number
DB18441
Background

Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Fusion proteins
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • 1-118-Signal regulatory protein α (human) fusion protein with immunoglobulin G4 [128-proline] (human γ4-chain C region C-terminal fragment), dimer
  • SIRPA-IGG4-FC FUSION PROTEIN TTI-622
External IDs
  • TTI 622
  • TTI-622
  • TTI622

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
44D51T6SZH
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)1
2RecruitingTreatmentRecurrent ALK Positive Large B-Cell Lymphoma / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation / Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / Recurrent Grade 3b Follicular Lymphoma / Recurrent Gray Zone Lymphoma / Recurrent High Grade B-Cell Lymphoma / Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements / Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified / Recurrent Intravascular Large B-Cell Lymphoma / Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type / Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma / Refractory ALK Positive Large B-Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation / Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / Refractory Grade 3b Follicular Lymphoma / Refractory High Grade B-cell Lymphoma (HGBCL) / Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements / Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified / Refractory Intravascular Large B-Cell Lymphoma / Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type / Refractory Primary Mediastinal Large B-Cell Cell Lymphoma / Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma1
1Active Not RecruitingTreatmentAcute Myeloid Leukemia / Diffuse Large B-Cell Lymphoma (DLBCL) / Lymphoma / Multiple Myeloma (MM)1
1Active Not RecruitingTreatmentLymphoma / Multiple Myeloma (MM)1
1Active Not RecruitingTreatmentMultiple Myeloma (MM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at September 23, 2023 00:04 / Updated at September 24, 2023 02:56